Next Science Ltd Asset Resilience Ratio
Next Science Ltd asset resilience ratio. Next Science Ltd (NXS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NXS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Next Science Ltd (2019–2024)
Asset resilience ratio of Next Science Ltd from 2019 to 2024. This chart shows how Next Science Ltd's Asset Resilience Ratio has changed over time. Read Next Science Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Next Science Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NXS asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Next Science Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Next Science Ltd Industry Peers by Asset Resilience Ratio
Compare Next Science Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Next Science Ltd Asset Resilience Ratio by Year (2019–2024)
Next Science Ltd asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Next Science Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$9.21 Million ≈ $6.52 Million |
-- |
| 2023-12-31 | 0.21% | AU$37.82K ≈ $26.76K |
AU$17.90 Million ≈ $12.67 Million |
+0.01pp |
| 2022-12-31 | 0.21% | AU$37.79K ≈ $26.74K |
AU$18.37 Million ≈ $13.00 Million |
-2.47pp |
| 2021-12-31 | 2.68% | AU$366.00K ≈ $258.97K |
AU$13.67 Million ≈ $9.68 Million |
-28.14pp |
| 2020-12-31 | 30.81% | AU$7.24 Million ≈ $5.12 Million |
AU$23.49 Million ≈ $16.62 Million |
-14.88pp |
| 2019-12-31 | 45.70% | AU$10.38 Million ≈ $7.34 Million |
AU$22.71 Million ≈ $16.07 Million |
-- |
About Next Science Ltd
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more